CoChat
Sign Up
Cited by 102Schizophrenia research and treatmentFatty Acid Research and HealthAntioxidant Activity and Oxidative Stress

The DOI matches its Crossref record; 34 of the 37 references it cites were found in a registry or an index.

The impact of ω-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: An open-label pilot study

Sivrioglu, E.Y., Kirli, S., Sipahioglu, D., Gursoy, B., Sarandöl, E.·2007·Progress in Neuro-Psychopharmacology and Biological Psychiatry
DOI 10.1016/j.pnpbp.2007.07.004
Open this paper in CoChat — free account

Abstract

Classical antipsychotics like haloperidol are suggested to increase oxidative stress and oxidative cell injury in the brain. Pro-oxidant effect of haloperidol may influence the course and treatment outcomes of schizophrenia. Dietary supplementation of either antioxidants or omega-3 fatty acids was found to improve symptoms of schizophrenia. Thus we decided to assess the impact of combining omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol. Ongoing haloperidol treatment of 17 schizophrenia patients was supplemented with 1000 mg capsule of omega-3 fatty acids (180 mg EPA+120 mg DHA) bid, vitamin E 400 IU bid and vitamin C 1000 mg/day. Patients were assessed with Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Negative Symptoms (SANS), Simpson Angus Scale (SAS) and Barnes Akathisia Rating Scale (BARS) over a 4 month period. Gluthatione peroxidase, superoxide dismutase, malondialdehyde, vitamin E and C levels were also evaluated at baseline and at the end of study. BPRS, SANS, SAS and BARS scores obtained at follow-up visits were significantly lower compared to baseline. Superoxide dismutase level was significantly lower at the end of study. No significant differences were detected in other laboratory parameters. Our results support the beneficial effect of the supplementation on positive and negative symptoms of schizophrenia as well as the severity of side effects induced by haloperidol. The effect of supplementation on akathisia is especially noteworthy and it has not been investigated in previous studies.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.pnpbp.2007.07.004

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Research works printed but not linked: 2

  1. Berger, 2004, Ethyl-eicosapentaenoic acid (E-EPA) supplementation in early psychosis: a double-blind randomised placebo-controlled add on study in 80 drug-naive first episode psychosis patients [abstract], Int J Neuropsychopharmacol, 7, s422
  2. Mahadik, 1997, Essential fatty acids in the treatment of schizophrenia, Drugs Today, 33, 5

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Sivrioglu, E. Y., Kirli, S., Sipahioglu, D., Gursoy, B., & Sarandöl, E.
Affiliations
Bursa Uludağ Üni̇versi̇tesi̇ (TR)
Corresponding author
Sivrioglu, E.Y.
ORCID
Sarandöl, E.
Venue
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Publisher
Elsevier BV
Published
2007-10
Volume
31
Issue
7
Pages
1493-1499
ISSN
0278-5846 (ISSN-L)
DOI
10.1016/j.pnpbp.2007.07.004
OpenAlex
W2040401967
Cited by
102
References
37
Citations by year
2026: 3 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 7 · 2021: 11 · 2020: 5 · 2019: 2 · 2018: 1 · 2017: 8 · 2016: 5 · 2015: 9 · 2014: 4 · 2013: 4 · 2012: 3
FWCI
4.62
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Bursa Uludag University - AVESIS (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
Keywords
schizophrenia, omega-3 fatty acids, vitamin E supplementation, vitamin C supplementation, haloperidol, antipsychotic adverse effects, akathisia, oxidative stress, antioxidant supplementation, superoxide dismutase, malondialdehyde, glutathione peroxidase, negative symptoms, positive symptoms
MeSH terms
Adolescent, Adult, Antioxidants, Ascorbic Acid, Erythrocytes, Female, Haloperidol, Humans, Male, Malondialdehyde, Middle Aged, Pilot Projects, Schizophrenia, Schizophrenic Psychology, Superoxide Dismutase, Antipsychotic Agents, Vitamin E, Lipid Peroxidation, Fatty Acids, Omega-3, Treatment Outcome, Akathisia, Drug-Induced

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review